Natriumcromoglicaat Bb (Sodium Cromoglicate)

Sodium cromoglicate works by stabilising mast cells and inhibiting calcium‑dependent degranulation. This blocks the release of histamine, leukotrienes and other inflammatory mediators that trigger allergic reactions. By preventing mediator release, the drug reduces airway inflammation and the cascade of symptoms associated with asthma, allergic rhinitis and related mast‑cell disorders.

The exact dose of Natriumcromoglicaat Bb is determined by the prescribing clinician based on the patient’s age, weight, severity of disease and response to therapy. Healthcare professionals tailor the regimen to achieve optimal prophylactic effect while monitoring for tolerability. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for sodium cromoglicate in pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Physicians should evaluate each case individually and discuss potential risks and alternatives with the patient.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing a quotation. The sales team then replies with pricing, availability, shipping details and any necessary import documentation.

Compared with antihistamines, sodium cromoglicate does not block histamine receptors but prevents its release, offering a prophylactic approach rather than symptomatic relief. Unlike inhaled corticosteroids, it has minimal systemic anti‑inflammatory activity and a lower risk of steroid‑related side effects, making it useful as an adjunct or alternative in patients who need mast‑cell stabilization without steroids.

Store Natriumcromoglicaat Bb at ambient temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and light. Do not refrigerate or freeze unless specifically instructed by the manufacturer. Ensure the container is tightly closed after each use to maintain stability.

The medication is taken orally, usually as a tablet or capsule, with a glass of water. It can be administered with or without food, but patients should follow the prescriber’s guidance on timing relative to meals. Consistent daily dosing is important to maintain mast‑cell stabilization and achieve the desired prophylactic effect.

Serious adverse reactions, although rare, include anaphylaxis, severe bronchospasm that worsens respiratory function, and hepatotoxicity indicated by abnormal liver enzyme levels. Patients should seek immediate medical attention if they experience signs of an allergic reaction such as difficulty breathing, swelling of the face or throat, or sudden worsening of asthma symptoms.

Individuals with a known hypersensitivity to sodium cromoglicate or any of the product’s excipients should avoid its use. It is also contraindicated in patients with uncontrolled severe asthma who rely on rescue inhalers, as it is not a substitute for acute bronchodilator therapy. Clinicians should assess each patient’s medical history before prescribing.